The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

NCT ID: NCT00741767

Last Updated: 2015-10-06

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-08-31
• Study Completion Date: 2012-02-29

Brief Summary

The purpose of this study is to determine if Advair Diskus improves sleep quality by reducing lung hyperinflation in COPD.

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a common and clinically important disease characterized by chronic, irreversible airflow obstruction. Poor sleep quality and insomnia are well described phenomena in patients with COPD. Several studies suggest sleep disturbance adversely affects quality of life and may worsen daytime pulmonary function in COPD patients. Improving sleep quality in patients with COPD, therefore, may not only improve health quality, but also attenuate the decline in daytime pulmonary function.

Previous studies investigating the effects of inhaled bronchodilators on sleep quality in COPD have shown conflicting results. These conflicting data prompted us to perform a retrospective study on patients with COPD and co-existing sleep apnea (OSA) investigating the effects of mechanical lung function impairment and lung hyperinflation on sleep. Our study found a significant correlation between increased lung hyperinflation and reduced sleep efficiency (a measure of sleep quality), and this relationship was preserved in a multivariable regression model.

We hypothesize that Advair Diskus improves sleep quality by reducing lung hyperinflation in COPD. To test this hypothesis, we propose a double-blinded, placebo controlled cross-over study of Advair Diskus in patients with COPD and lung hyperinflation.

It was mutually decided by the sponsor and principal investigator to terminate the study early due to study subject enrollment difficulties.

Conditions

Chronic Obstructive Pulmonary Disease; Sleep Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: QUADRUPLE

Study Groups

Salmeterol-fluticasone

Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks. Patients will cross-over and receive placebo medication for 4 weeks later in the study.

Group Type: OTHER

salmeterol-fluticasone

Intervention Type: DRUG

250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily

Placebo

Patients randomized to receive placebo medication twice daily for 4 weeks. Patients will cross-over and receive study medication later in the study.

Group Type: OTHER

salmeterol-fluticasone

Intervention Type: DRUG

250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily

Interventions

salmeterol-fluticasone

250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily

Intervention Type: DRUG

Other Intervention Names

Advair Diskus

Eligibility Criteria

Inclusion Criteria

• Age ≥ 40 years of age
• BMI<30
• Former smokers with ≥ 10 pack-year history
• Diagnosis of COPD, as defined by the American Thoracic Society (FEV1/FVC < 70 with history of exposure to noxious particles or gases)
• Moderate to severe COPD as defined as an FEV1 ≤ 80% predicted
• Functional residual capacity > 120% or inspiratory capacity < 80% predicted on pulmonary function testing
• Poor subjective sleep quality: All subjects included must answer "yes" to at least one of the following questions:

1. Do you have trouble falling asleep?

2. Do you have trouble staying asleep?

3. Do you not get enough sleep?

4. Do you wake up too early and not be able to get back to sleep?

5. Do you fall asleep during the day?

Exclusion Criteria

• Conditions that in the judgment of the investigator would interfere with subject participation in the study
• BMI > 30
• History of or physician diagnosed pulmonary disorder other than COPD
• History of significant obstructive sleep disordered breathing (apnea-hypopnea index > 15) or presence of central sleep apnea
• History of narcolepsy, primary hypersomnia, periodic limb movement disorder, or parasomnia
• History of psychiatric illness
• Presence of decompensated heart failure
• Use of prednisone, antibiotic therapy, or new medication for COPD in the previous 3 months
• Use of any sleep aids
• History of ≥ 1 COPD exacerbation (defined as requiring oral corticosteroids and/or antibiotics as either an outpatient or inpatient)
• Known allergy or significant adverse reactions to inhaled beta2-agonists and inhaled corticosteroids (not including thrush and dysphonia)
• Pregnancy or lactating
• Inability or unwillingness to provide informed consent
• Inability to effectively use study medication or perform baseline measurements
• Inability to be contacted by phone

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

Northwestern University

OTHER

Sponsor Role: lead

Responsible Party

Ravi Kalhan

Assistant Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ravi Kalhan, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Northwestern University

Locations

Northwestern University

Chicago, Illinois, United States

Countries

United States

Other Identifiers

3582

Identifier Type: -

Identifier Source: org_study_id